Trial Profile
An Open-label, Pharmacokinetic and Tolerability Study of SAR302503 Given as a Single 300 mg Dose in Subjects With Mild and Moderate Hepatic Impairment, and in Matched Subjects With Normal Hepatic Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Mar 2021
Price :
$35
*
At a glance
- Drugs Fedratinib (Primary)
- Indications Cancer; Myelofibrosis
- Focus Pharmacokinetics
- Acronyms the hepatic study
- Sponsors Sanofi
- 01 Mar 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 Jan 2013 New trial record